Komori
Share Issuance and Disposal4502Takeda Pharmaceutical Company LimitedPharmaceuticals

Notice Regarding the Withdrawal of the Shelf Registration for the Issuance of New Shares and a New Shelf Registration

The company decided to withdraw the shelf registration for the issuance of new shares filed on 2 June 2025 and file a new shelf registration, effective for one year from 9 June 2026, in preparation for the issuance of new shares or disposal of treasury shares in connection with the LTIP for overseas group employees.

Worth reading
45Recurring
Scored from 4 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
240000
¥ million (maximum planned issue amount)
Wording
Conditional
How definitive the wording is.

Details of issuance or disposal

Issuance of new shares or disposal of treasury shares under the LTIP as an incentive plan for overseas group employees

Intended allottee
Overseas group employees (number of employees and number of shares: Not disclosed)
Amount of funds to be raised

Not intended to raise funds

Specific use of funds
Not intended to raise funds
発行済株式総数

Approximately 1.1% in total (expected dilution from the vesting of rights under the LTIP and other plans during fiscal 2026)

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Categories and Number of Persons Covered
Overseas group employees (number of employees and number of allocated shares: Not disclosed)
Most recent equity financing
Timing 2 June 2025 / Type Shelf registration for the issuance of new shares / Amount Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalIssuance of new shares or disposal of treasury shares under the LTIP as an incentive plan for overseas group employees
Amount of funds to be raisedNot intended to raise funds
Specific use of fundsNot intended to raise funds
Intended allotteeOverseas group employees (number of employees and number of shares: Not disclosed)
Dilution RateApproximately 1.1% in total (expected dilution from the vesting of rights under the LTIP and other plans during fiscal 2026)
Categories and Number of Persons CoveredOverseas group employees (number of employees and number of allocated shares: Not disclosed)
Most recent equity financingTiming 2 June 2025 / Type Shelf registration for the issuance of new shares / Amount Not disclosed
Items this document does not state (21)
Number of shares to be issued or disposed ofIssue price and disposal priceTotal issue valueEstimated issuance expensesPayment dateIntended allottee's holding policyTotal number of issued sharesBasis for determining the amount to be paidExercise priceExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To enable the flexible issuance of new shares or disposal of treasury shares in connection with the continued implementation of the LTIP for overseas group employees. This is not intended to raise funds.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Withdrawal of the Shelf Registration for the Issuance of New Shares and a New Shelf Registration | Takeda Pharmaceutical Company Limited (4502) timely disclosure | Komori